Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease
NCT00430625 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease
- Lead sponsor
- Shire
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 15, 2007
- Completion date
- April 1, 2009
- Enrollment
- 25 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
gaucher disease, type 1